Cardiotoxicity Induced by Trastuzumab Therapy in HER2-positive Breast Cancer

Share this content:

the Cancer Therapy Advisor take:

Trastuzumab therapy appears to be a safe treatment option for patients with asymptomatic treatment-induced cardiotoxicity (left ventricular ejection fraction [LVEF] of ≥50%), according to an article published online in the journal The Oncologist.

The authors studied patients with HER2-positive breast cancer who were administered adjuvant trastuzumab between 2005 and 2010.

An absolute decrease in LVEF of greater than or equal to 10% to below 55% or an absolute decline of greater than or equal to 16% was the definition of treatment-induced cardiotoxicity for this study.

Results showed 92 out of 573 (16%) patients developed trastuzumab treatment-induced cardiotoxicity. Thirty-one of these 92 patients were able to continue receiving trastuzumab without interruption—all patients were asymptomatic at cardiotoxicity diagnosis (LVEF of ≥50%) with a median LVEF of 53% (range, 50%–63%), and no patients were reported to have developed heart failure during follow-up.

Furthermore, treatment-induced cardiotoxicity related risk factors included age (P =0.011), anthracycline chemotherapy (P =0.002), and lower pretrastuzumab LVEF (P<0.001).

Increased mammography screening can lead to overdiagnosis.
Trastuzumab therapy appears to be a safe treatment option for patients with asymptomatic treatment-induced cardiotoxicity.
Departments of Medicine and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA Correspondence: Anthony F. Yu, M.D., Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA. Telephone: 212-639-7932; E-Mail: yua3{at} Received March 24, 2015. Accepted June 8, 2015. Published online before print August 3, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs